Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome

Many patients require revascularization after index acute coronary syndrome (ACS). Lipoprotein(a) is thought to play a pathogenic role in atherothrombosis. In ODYSSEY OUTCOMES, alirocumab reduced major adverse cardiovascular events after ACS, with greater reduction among those with higher lipoprotei...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Canadian journal of cardiology 2023-10, Vol.39 (10), p.1315-1324
Hauptverfasser:	Steg, P. Gabriel, Szarek, Michael, Valgimigli, Marco, Islam, Shahidul, Zeiher, Andreas M., Bhatt, Deepak L., Bittner, Vera A., Chiang, Chern-En, Diaz, Rafael, Goodman, Shaun G., Gotcheva, Nina, Harrington, Robert A., Jukema, J. Wouter, Kim, Hyo-Soo, Kim, Sang-Hyun, Morais, Joao, Pordy, Robert, Scemama, Michel, White, Harvey D., Schwartz, Gregory G., Steg, Ph. Gabriel
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute coronary syndrome Alirocumab Higher lipoprotein(a) Treatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!